Tagged with A

Sanofi Aventis Malaysia Pharmaceutical Executive is a magazine about executives, their experience and their perspectives on the pharmaceutical industry. You have worked in Australia, Hong Kong and now you are the general manager of Malaysia, Singapore and Brunei. For the interest of our readers could you give an overview of what path you…

IMS Health Malaysia You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to join the world of consultancy, how useful was this insider knowledge to your work and what is it like now…

Ranbaxy (UK) Ltd. (RUKL) You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish it from your previous position? Obviously there are quite a lot of challenges in moving from one continent to another,…

Alliance Pharma Plc Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we take a look back in time, can you explain what your drivers were to set up the company in 1998?…

National Institute for Health and Clinical Excellence (NICE) Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed out that NICE is admired globally for its evidence-based guidelines and the economic rigour of its Health Technology Assessments (HTAs).…

Amgen B.V. You are still relatively new to the Netherlands having been here for one year. This must be a very insightful experience abroad. What were your initial expectations and first impressions when first starting here and how have they evolved over the course of your year as head of Amgen in…

Lilly Nederland BV You began as managing director of this Dutch affiliate close to one year ago. What was the trajectory that led you to this position and what were your initial impressions of the Netherlands when first taking over? I joined Lilly eight years ago, starting on the finance side and then…

Eli Lilly Malaysia You have spent much of your time working in the USA and came to Malaysia in 2008 as Country Manager. What were your expectations of Malaysia before you arrived and how have you enjoyed adapting to this ethnically diverse country? The opportunity has been enjoyable on a number of levels.…

Astellas Pharma Ltd. Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan and Asia. Approximately 20% is in the U.S.; and approximately 20% is in Europe. So Europe still represents a vast—and…

Galapagos NV Since its founding Galapagos has operated with a hybrid business model which has combined its internal discoveries with service activities. This model has worked quite well as it has now pushed the company into profitability. Would you say that everything has turned out according to plan or have you exceeded…

Bayer BV Netherlands As much as this report is about business trends and insights, we also like to portray the personalities of the industry in the markets that we cover. What has been your professional trajectory that led you to the head of Bayer Schering Pharma here in the Netherlands? I am originally…

Shire International Licensing BV Netherlands Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these four continents. What is the strategic role that Shire Netherlands plays and how does this role fit into the group’s…